Aktienanalyse zu Aclarion Inc (ACON)ACONAclarion Inc

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Currently, Aclarion Inc (ACON) is not a strong buy. The stock is trading at $1.68, which is significantly down 76.86% over the past year, indicating a bearish trend. The RSI is at 31.31, suggesting it is oversold, but this could also mean continued downward pressure. The forward P/E is 0, indicating uncertainty in future earnings, and the gross margin has improved to 32.91% in Q2 2026, up from negative margins previously. The main risk is the upcoming earnings report on November 11, 2026, where the EPS estimate is -1.05, which could further impact the stock negatively if results disappoint.